Central lab vs local labs in clinical trials: how sponsors decide

A central lab tests every specimen in a study at one designated laboratory, so results share the same methods, reference ranges and data format. Local labs test near each participant, which is faster and easier for routine safety tests. Many sponsors use both: local labs for well-standardized safety checks, and a central lab for endpoints and trial-specific tests.
That's the short answer. This guide is for sponsors, CROs and research teams deciding where their study's specimens should go, and what to ask before they choose. It's general operational guidance, not regulatory or legal advice, so check your plan with your own regulatory and quality teams.
What "central lab" and "local lab" mean
A central lab is one laboratory (or one tightly controlled lab organization) named in the protocol to run the study's testing. Specimens come to it from every site, or from participants' homes.
A local lab is whatever qualified clinical lab is close to the site or the participant: a hospital lab, a reference lab draw site, or the site's own lab.
FDA's guidance on conducting clinical trials with decentralized elements draws the line clearly. It says local clinical laboratory facilities are generally appropriate for routine clinical tests that are well standardized, while designated laboratories should be used for tests that are specialized or specific to the trial. It also notes that specimens may be collected by remote trial staff, local providers, local labs or by participants using home collection kits, then sent to a designated lab for processing.
Why sponsors choose a central lab
The main reason is consistency. When every result comes from the same lab, the same analyzers, assays and reference ranges apply to every participant. That matters most for:
Primary and key secondary endpoints, where differences between labs can add noise you then have to explain in analysis.
Trial-specific or specialized assays that local labs don't run, or run with different methods.
Longitudinal comparisons, where a participant's change over time is the result that counts.
Clean data delivery, with one data format and one data transfer agreement instead of many.
Oversight is simpler too. The ICH E6(R3) good clinical practice guideline, which FDA published as final guidance in 2025, asks sponsors to address monitoring of important data and processes performed outside the investigator site, naming central laboratories as an example, in the monitoring plan. Monitoring one lab is usually easier than qualifying and monitoring dozens.
Why sponsors use local labs
Local labs have real strengths:
Speed for safety decisions. A local result can be back the same day, which helps when an investigator needs a value before dosing.
Less shipping. No courier or cold-chain step for each specimen, and less risk of samples arriving too late to test.
Participant convenience. Participants can often use a lab near home or work.
Standard tests. Routine chemistry and hematology are well standardized across qualified labs, which is exactly the case FDA's guidance describes as generally appropriate for local testing.
The trade-off is variation. Different labs mean different methods, units and reference ranges, more vendors to qualify, and more work to bring data into one format.
Central vs local labs at a glance
Consistency: a central lab uses one set of methods and reference ranges for every participant; local labs vary.
Best fit: a central lab suits endpoints, trial-specific assays and long-term trends; local labs suit routine, well-standardized safety tests.
Speed of a single result: central results depend on shipping time; local results are often faster.
Logistics: a central lab means planning kits, shipping and specimen stability; local labs mean fewer shipments but more vendors.
Data: a central lab delivers one format; local labs leave you normalizing many.
Oversight: one central lab to qualify and monitor, versus many local labs.
The hybrid model most studies end up with
In practice, many protocols split the work. Local labs handle routine safety tests where speed matters. A central lab runs the endpoint and trial-specific testing. When a study adds home collection, participants collect specimens with standardized kits and ship them straight to the central lab, which keeps endpoint data consistent without asking participants to travel.
If you use local labs for anything that feeds analysis, plan how you'll handle different reference ranges and units up front, rather than at database lock.
Regulatory basics to confirm with any lab
Whatever model you choose, check a few basics:
CLIA certification. CMS explains in its research testing and CLIA overview that research testing which reports patient-specific results that will be or could be used for health assessment, diagnosis or treatment is presumed to be subject to CLIA. Ask for the lab's CLIA number and certificate type.
State licenses. Some states regulate labs testing their residents' specimens. For example, New York's Clinical Laboratory Evaluation Program says only labs holding a New York State clinical laboratory permit may test specimens that originate from New York.
Form FDA 1572. For drug trials under an IND, FDA's decentralized trials guidance notes that all clinical laboratory facilities must be listed on Form FDA 1572.
Shipping rules. Specimens shipped by mail or courier have packaging requirements, such as the US Department of Transportation's exempt human specimen rules for many diagnostic specimens.
Questions to ask a central lab
When you compare central lab partners, ask:
Which of your protocol's tests run in-house, and which are sent to another lab?
Which tests are validated for the specimen types you plan to use, including home-collected specimens?
What CLIA certificate and state licenses does the lab hold?
How long are specimens stable in transit, and what happens when one arrives outside that window?
Can the lab build, label and ship study kits, including direct-to-participant kits with return shipping?
How are kit and specimen status tracked, and can your team see them?
How are results delivered: portal, API or scheduled data transfer?
How are critical or unexpected values communicated, and to whom?
What turnaround should you expect for each test, and how is it measured?
IHDLab supports remote and hybrid studies as a CLIA-certified lab (CLIA 05D2040304) licensed in California, New York and Maryland. We build and ship standardized kits and test specimens in our own lab; our clinical research lab services page has the details. For kit design and shipping alone, see our white-label test kits. For planning home collection more broadly, our earlier guide to lab testing in decentralized clinical trials goes deeper.
The bottom line
Central versus local isn't an all-or-nothing choice. Use local labs where speed matters and the tests are well standardized, and use a central lab for the results your study's conclusions depend on. Decide early, write it into the protocol and monitoring plan, and choose a lab partner that can show you exactly how specimens and data will move.



